Disease management
The funding brings the company's Series C funding round to a close and total capital raised to $155 million.
The company will use the funds to accelerate the development of its Ellipse Spinal Cord Stimulator Platform, used to treat chronic pain.
The chronic care management and remote patient monitoring company will be led by veteran healthcare executive Asif Ahmad.
The funding comes more than a year after the company closed an oversubscribed $31.4 million Series B round.
The company will use the funds to accelerate the commercialization of its TAPS therapy and enhance the visibility of its offerings among providers and patients.
The company will use the funds to expand its commercial growth and clinical-evidence generation.
Individuals can check whether the musculoskeletal platform is covered via their employer or health plan on Amazon's platform - and, if eligible, connect with Hinge's care team.
The announcement comes two months after the pair revealed at the UN General Assembly its intent to expand Zipline infrastructure to improve care access nationwide.
The AI models only utilise wearable sleep and circadian rhythm data to analyse patterns driving mood disorders.
Jake Leach, executive VP and chief operating officer at Dexcom, joined MobiHealthNews to discuss the company's evolution and offerings beyond diabetes.